Editas Medicine, Inc.

LSE:0IFK Stock Report

Market Cap: US$182.4m

Editas Medicine Valuation

Is 0IFK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0IFK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0IFK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0IFK's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0IFK?

Key metric: As 0IFK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0IFK. This is calculated by dividing 0IFK's market cap by their current revenue.
What is 0IFK's PS Ratio?
PS Ratio3x
SalesUS$61.76m
Market CapUS$182.43m

Price to Sales Ratio vs Peers

How does 0IFK's PS Ratio compare to its peers?

The above table shows the PS ratio for 0IFK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
AVCT Avacta Group
7.8x0.4%UK£175.6m
BVXP Bioventix
14.4xn/aUK£195.7m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AREC Arecor Therapeutics
5.9x35.2%UK£28.9m
0IFK Editas Medicine
3x14.3%US$182.4m

Price-To-Sales vs Peers: 0IFK is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (7.4x).

Price to Sales Ratio vs Industry

How does 0IFK's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.9x19.5%
0IFK Editas Medicine
 3x14.3%US$182.43m
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.6x21.0%US$561.69m
0IFK 3.0xIndustry Avg. 7.9xNo. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.9x37.3%
0IFK Editas Medicine
 3x-0.7%US$182.43m
No more companies

Price-To-Sales vs Industry: 0IFK is good value based on its Price-To-Sales Ratio (3x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is 0IFK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0IFK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: 0IFK is expensive based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0IFK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.20
US$8.21
+273.4%
44.7%US$15.00US$1.00n/a14
Nov ’25US$2.96
US$11.63
+292.7%
43.8%US$23.00US$3.00n/a16
Oct ’25US$3.25
US$13.50
+315.4%
44.4%US$27.00US$7.00n/a16
Sep ’25US$3.70
US$13.53
+265.8%
45.7%US$27.00US$7.00n/a15
Aug ’25US$5.16
US$14.27
+176.6%
42.9%US$27.00US$7.00n/a15
Jul ’25US$4.66
US$14.47
+210.8%
41.2%US$27.00US$7.00n/a15
Jun ’25US$5.22
US$14.60
+179.7%
40.7%US$27.00US$7.00n/a15
May ’25US$5.28
US$15.40
+191.7%
35.0%US$27.00US$7.00n/a15
Apr ’25US$7.46
US$15.40
+106.4%
35.0%US$27.00US$7.00n/a15
Mar ’25US$10.89
US$15.40
+41.4%
35.0%US$27.00US$7.00n/a15
Feb ’25US$7.20
US$15.21
+111.3%
37.7%US$27.00US$7.00n/a14
Jan ’25US$10.18
US$14.67
+44.1%
40.0%US$27.00US$7.00n/a15
Dec ’24US$10.74
US$13.53
+26.0%
44.1%US$27.00US$7.00n/a15
Nov ’24US$6.85
US$13.53
+97.6%
43.7%US$30.00US$7.00US$2.9615
Oct ’24US$7.79
US$13.63
+74.9%
42.0%US$30.00US$7.00US$3.2516
Sep ’24US$9.19
US$13.18
+43.5%
42.4%US$30.00US$7.00US$3.7017
Aug ’24US$8.58
US$13.41
+56.3%
43.4%US$30.00US$7.00US$5.1617
Jul ’24US$8.28
US$13.41
+62.0%
43.4%US$30.00US$7.00US$4.6617
Jun ’24US$9.60
US$12.71
+32.3%
47.0%US$30.00US$7.00US$5.2217
May ’24US$8.23
US$12.71
+54.4%
47.6%US$30.00US$7.00US$5.2817
Apr ’24US$7.32
US$13.06
+78.3%
45.7%US$30.00US$7.00US$7.4617
Mar ’24US$8.84
US$13.06
+47.8%
45.7%US$30.00US$7.00US$10.8917
Feb ’24US$9.98
US$14.24
+42.6%
59.1%US$36.00US$7.00US$7.2017
Jan ’24US$8.62
US$16.38
+90.1%
74.1%US$50.00US$7.00US$10.1816
Dec ’23US$10.01
US$17.27
+72.5%
70.8%US$50.00US$7.00US$10.7415
Nov ’23US$12.79
US$28.93
+126.2%
69.0%US$80.00US$8.00US$6.8515

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%